The company says it will leverage the new capital to expand commercialization and clinical research efforts for its suite of cardiac imaging analysis products.
This next-generation AlphaFold signifies a dramatic leap in performance and showcases the potential of AI to enhance our understanding of molecular biology.
In a recently published paper in Science, it was revealed that AlphaMissense had classified a staggering 89% of all possible missense variants — illuminating the pathogenic or benign nature of these mutations.
The platform aims to merge artificial intelligence with healthcare data, offering research professionals an integrated suite of tools that could radically reduce the timeline for medical discovery.
Funding will advance pipeline of 17 existing programs and approximately 10 new starts annually.
The companies believe the model will enable major leaps in accuracy as well as entirely new capabilities for cancer detection and diagnostics.
Investors are betting big on startups like Inceptive that are merging biotech and AI. This funding round triples Inceptive's valuation to over $300 million since it's $20M seed round in 2021.
Not only does the implant use Ann's brain signals to generate speech, but it also animates a digital avatar with facial expressions, mimicking the natural nuances of human communication.
The oversubscribed round was co-led by an undisclosed U.S. life sciences investor and returning lead investor Andreessen Horowitz.
Learn about the groundbreaking impact of generative AI in healthcare, including faster drug discovery, more accurate diagnosis, personalized treatment, and efficient operations.